These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19828867)

  • 1. MRI lesion loads and disability relationships in MS: more similar than different?
    Wolinsky JS
    Neurology; 2009 Nov; 73(19):1524-5. PubMed ID: 19828867
    [No Abstract]   [Full Text] [Related]  

  • 2. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis].
    Lebrun C
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of MRI in the diagnosis and the natural course of multiple sclerosis].
    Tourbah A; Lyon-Caen O
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):757-60. PubMed ID: 11677395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic criteria of multiple sclerosis with reference to different clinical forms].
    Dimitri D
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):914-28. PubMed ID: 11787356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
    Minneboo A; Uitdehaag BM; Jongen P; Vrenken H; Knol Dl; van Walderveen MA; Polman CH; Castelijns JA; Barkhof F
    Mult Scler; 2009 May; 15(5):632-7. PubMed ID: 19389751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?
    Strasser-Fuchs S; Enzinger C; Ropele S; Wallner M; Fazekas F
    Mult Scler; 2008 Mar; 14(2):205-11. PubMed ID: 17986507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging.
    Rovaris M; Filippi M
    Neurol Sci; 2005 Dec; 26 Suppl 4():S204-8. PubMed ID: 16388359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary progressive multiple sclerosis: progress and challenges.
    Rice CM; Cottrell D; Wilkins A; Scolding NJ
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1100-6. PubMed ID: 23418213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of follow-up and disease course].
    Roullet E
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1121-3. PubMed ID: 11787343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No shortcuts to outcome in MS clinical trials?
    Koch-Henriksen N
    Neurology; 2009 Feb; 72(8):686-7. PubMed ID: 19237696
    [No Abstract]   [Full Text] [Related]  

  • 13. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI time series modeling of MS lesion development.
    Meier DS; Guttmann CR
    Neuroimage; 2006 Aug; 32(2):531-7. PubMed ID: 16806979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
    Korteweg T; Rovaris M; Neacsu V; Filippi M; Comi G; Uitdehaag BM; Knol DL; Polman CH; Barkhof F; Vrenken H;
    Mult Scler; 2009 Apr; 15(4):465-71. PubMed ID: 19091881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (1)H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis.
    Caramanos Z; DiMaio S; Narayanan S; Lapierre Y; Arnold DL
    J Neurol Sci; 2009 Jul; 282(1-2):72-9. PubMed ID: 19232641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender-related differences in MS: a study of conventional and nonconventional MRI measures.
    Antulov R; Weinstock-Guttman B; Cox JL; Hussein S; Durfee J; Caiola C; Dwyer MG; Bergsland N; Abdelrahman N; Stosic M; Hojnacki D; Munschauer FE; Miletic D; Zivadinov R
    Mult Scler; 2009 Mar; 15(3):345-54. PubMed ID: 19028830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrophy in white matter fiber tracts in multiple sclerosis is not dependent on tract length or local white matter lesions.
    Kezele IB; Arnold DL; Collins DL
    Mult Scler; 2008 Jul; 14(6):779-85. PubMed ID: 18611990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress of therapy in patients with multiple sclerosis].
    Kümpfel T; Havla J; Hohlfeld R
    MMW Fortschr Med; 2010 Mar; 152(9):42-4. PubMed ID: 20384096
    [No Abstract]   [Full Text] [Related]  

  • 20. A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio.
    Dwyer M; Bergsland N; Hussein S; Durfee J; Wack D; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):86-95. PubMed ID: 19386319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.